CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 14,151 enrolled
Drug / intervention
candesartan cilexetildrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02166697
NCT02166697N/ACompleted

Candesartan Cilexetil Tablets Specified Drug-use Survey "Hypertension: Survey on Patients With Metabolic Syndrome"

Takeda·observational·Posted Jun 18, 2014·Updated Sep 28, 2016

In Brief

An observational study evaluating candesartan cilexetil for Hypertension. Completed, enrolled 14,151 participants.

Detailed Summary

The purpose of this survey is designed to investigate the treatment status of hypertensive patient with metabolic syndrome-related risk factors treated with candesartan cilexetil tablets (Blopress Tablets), as well as to assess relationships between risk factors (example, visceral fat accumulation) and the incidence of cerebrovascular/cardiovascular events in an exploratory manner.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
Countries--
Collaborators--

Timeline

N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 18, 2014
Enrollment StartJun 1, 2006
Primary CompletionNov 1, 2010
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 12.0 years ago

Interventions

candesartan cilexetildrug

candesartan cilexetil tablets